← Back to Screener
Personalis, Inc. Common Stock (PSNL)
Price$6.34
Favorite Metrics
Price vs S&P 500 (26W)-25.87%
Price vs S&P 500 (4W)-16.79%
Market Capitalization$704.17M
All Metrics
Book Value / Share (Quarterly)$2.55
P/TBV (Annual)0.36x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)2.30%
Cash Flow / Share (Quarterly)$-0.78
Price vs S&P 500 (YTD)-19.59%
Gross Margin (TTM)22.65%
Net Profit Margin (TTM)-116.69%
EPS (TTM)$-0.91
10-Day Avg Trading Volume1.33M
EPS Excl Extra (TTM)$-0.91
Revenue Growth (5Y)-2.40%
EPS (Annual)$-0.91
ROI (Annual)-30.50%
Gross Margin (Annual)22.65%
Net Profit Margin (5Y Avg)-122.13%
Cash / Share (Quarterly)$2.34
Revenue Growth QoQ (YoY)3.24%
ROA (Last FY)-24.32%
Revenue Growth TTM (YoY)-17.69%
EBITD / Share (TTM)$-0.88
ROE (5Y Avg)-45.56%
Operating Margin (TTM)-126.43%
Cash Flow / Share (Annual)$-0.78
P/B Ratio2.70x
P/B Ratio (Quarterly)2.71x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)8.40x
Net Interest Coverage (TTM)-11.43x
ROA (TTM)-29.31%
EPS Incl Extra (Annual)$-0.91
Current Ratio (Annual)6.76x
Quick Ratio (Quarterly)6.46x
3-Month Avg Trading Volume1.44M
52-Week Price Return104.56%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.08
P/S Ratio (Annual)10.11x
Asset Turnover (Annual)0.21x
52-Week High$11.50
Operating Margin (5Y Avg)-122.15%
EPS Excl Extra (Annual)$-0.91
CapEx CAGR (5Y)6.74%
26-Week Price Return-17.12%
Quick Ratio (Annual)6.46x
13-Week Price Return-27.63%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)6.76x
Enterprise Value$585.183
Revenue / Share Growth (5Y)-19.36%
Asset Turnover (TTM)0.25x
Book Value / Share Growth (5Y)-12.55%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)8.92x
Pretax Margin (Annual)-116.66%
Cash / Share (Annual)$2.34
3-Month Return Std Dev88.24%
Gross Margin (5Y Avg)27.34%
Net Income / Employee (TTM)$-0
ROE (Last FY)-31.12%
Net Interest Coverage (Annual)-14.75x
EPS Basic Excl Extra (Annual)$-0.91
Receivables Turnover (TTM)5.72x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$-0.91
Receivables Turnover (Annual)5.72x
ROI (TTM)-38.49%
P/S Ratio (TTM)10.11x
Pretax Margin (5Y Avg)-122.08%
Revenue / Share (Annual)$0.78
Tangible BV / Share (Annual)$4.67
Price vs S&P 500 (52W)69.46%
Year-to-Date Return-15.45%
5-Day Price Return6.66%
EPS Normalized (Annual)$-0.91
ROA (5Y Avg)-31.54%
Net Profit Margin (Annual)-116.69%
Month-to-Date Return5.65%
Cash Flow / Share (TTM)$-2.14
EBITD / Share (Annual)$-0.88
Operating Margin (Annual)-126.43%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-44.84%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.91
P/TBV (Quarterly)0.51x
P/B Ratio (Annual)2.71x
Inventory Turnover (TTM)8.92x
Pretax Margin (TTM)-116.66%
Book Value / Share (Annual)$2.55
Price vs S&P 500 (13W)-30.50%
Beta2.15x
Revenue / Share (TTM)$0.75
ROE (TTM)-39.13%
52-Week Low$3.09
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.15
4.15
4.15
4.15
Industry Peers — Health Services(20)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
PSNLPersonalis, Inc. Common Stock | — | -17.69% | -126.43% | -39.13% | $6.34 |
NTRANatera, Inc. Common Stock | — | 35.90% | -13.44% | -15.28% | $207.74 |
LHLabcorp Holdings Inc. | 25.31x | 7.25% | 9.92% | 10.28% | $269.19 |
DGXQuest Diagnostics Inc. | 21.75x | 11.78% | 14.10% | 13.88% | $196.31 |
EXASExact Sciences Corp | — | 17.69% | -6.35% | -8.51% | $104.91 |
GHGuardant Health, Inc. Common Stock | — | 32.88% | -45.02% | -246.60% | $91.07 |
RDNTRadNet, Inc. Common Stock | 1779.27x | 11.51% | 3.04% | -1.88% | $57.85 |
VCYTVeracyte, Inc. | 39.66x | 16.01% | 11.17% | 5.33% | $33.45 |
GRALGRAIL, Inc. Common Stock | — | 17.18% | -381.98% | -17.11% | $51.20 |
CDNACareDx, Inc. | 18.34x | 13.79% | -8.10% | -6.47% | $21.29 |
FTREFortrea Holdings Inc. Common Stock | — | 1.00% | -32.04% | -152.17% | $10.44 |
About
Personalis Inc provides genomic sequencing and analytics solutions that enable the development of personalized cancer vaccines and cancer immunotherapies. The company's portfolio includes ImmunoID NeXT and related diagnostic tests, serving pharmaceutical companies developing next-generation cancer treatments.